Soligenix (SNGX) Non Operating Income (2013 - 2026)
Soligenix's (SNGX) quarterly Non Operating Income came in at $59873.0 in Q1 2026, down 20.42% YoY from $75240.0 in Q1 2025, and down 0.67% on a QoQ basis from $60279.0 in Q4 2025.
Soligenix (SNGX) Non Operating Income (2013 - 2026) Analysis & Trends
Soligenix (SNGX) has 13 years of Non Operating Income data on file, last reported at $59873.0 in Q1 2026.
- Quarterly Non Operating Income fell 20.42% year-over-year to $59873.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $231591.0 (up 164.82% YoY) and the FY2025 annual result came in at $258481.0, up 20.8% from the prior year.
- Non Operating Income declined to $59873.0 in Q1 2026, from $60279.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $145855.0 in Q3 2024 to a low of -$288630.0 in Q4 2023.
- A 5-year average of -$41985.5 and a median of $28842.0 in 2024 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income plunged 164.54% — and 2024, when it soared 447.39%.
- Tracing SNGX's Non Operating Income over 5 years: stood at -$180843.0 in 2022, then slumped by 59.6% to -$288630.0 in 2023, then rose by 18.99% to -$233817.0 in 2024, then surged by 125.78% to $60279.0 in 2025, then declined by 0.67% to $59873.0 in 2026.
- The last three Non Operating Income figures came in at $59873.0 (Q1 2026), $60279.0 (Q4 2025), and $49536.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - | 112,109.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 112,109.00 |
| Mar 31, 2026 | 59,873.00 |
| Dec 31, 2025 | 60,279.00 |
| Sep 30, 2025 | 49,536.00 |
| Jun 30, 2025 | 61,903.00 |
| Mar 31, 2025 | 75,240.00 |
| Dec 31, 2024 | -233,817.00 |
| Sep 30, 2024 | 145,855.00 |
| Jun 30, 2024 | 100,173.00 |
| Mar 31, 2024 | 28,842.00 |
| Dec 31, 2023 | -288,630.00 |
| Sep 30, 2023 | 66,363.00 |
| Jun 30, 2023 | 18,300.00 |
| Mar 31, 2023 | -103,568.00 |
| Dec 31, 2022 | -180,843.00 |
| Sep 30, 2022 | -215,146.00 |
| Jun 30, 2022 | -146,399.00 |
| Mar 31, 2022 | -211,714.00 |
| Dec 31, 2021 | -779,840.00 |
| Sep 30, 2021 | -227,271.00 |